CN105142655B - 由撕裂蜡孔菌培养基制备的提取物用于治疗糖尿病和糖尿病并发症 - Google Patents

由撕裂蜡孔菌培养基制备的提取物用于治疗糖尿病和糖尿病并发症 Download PDF

Info

Publication number
CN105142655B
CN105142655B CN201380070856.XA CN201380070856A CN105142655B CN 105142655 B CN105142655 B CN 105142655B CN 201380070856 A CN201380070856 A CN 201380070856A CN 105142655 B CN105142655 B CN 105142655B
Authority
CN
China
Prior art keywords
culture
exopolysaccharide
extract
ceriporia
lacerata
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380070856.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105142655A (zh
Inventor
金秉千
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kin Kin Biological Pharmaceutical Co ltd
Original Assignee
Kin Kin Biological Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kin Kin Biological Pharmaceutical Co ltd filed Critical Kin Kin Biological Pharmaceutical Co ltd
Publication of CN105142655A publication Critical patent/CN105142655A/zh
Application granted granted Critical
Publication of CN105142655B publication Critical patent/CN105142655B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
CN201380070856.XA 2013-01-18 2013-01-18 由撕裂蜡孔菌培养基制备的提取物用于治疗糖尿病和糖尿病并发症 Active CN105142655B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2013/000398 WO2014112666A1 (fr) 2013-01-18 2013-01-18 Méthode de préparation d'un extrait du milieu de culture du ceriporia lacerata et composition pharmaceutique obtenue à l'aide de la méthode pour prévenir ou traiter des pathologies diabétiques et des complications liées au diabète, contenant l'extrait du milieu de culture du ceriporia lacerata comme principe actif

Publications (2)

Publication Number Publication Date
CN105142655A CN105142655A (zh) 2015-12-09
CN105142655B true CN105142655B (zh) 2020-11-17

Family

ID=51209750

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380070856.XA Active CN105142655B (zh) 2013-01-18 2013-01-18 由撕裂蜡孔菌培养基制备的提取物用于治疗糖尿病和糖尿病并发症

Country Status (9)

Country Link
JP (1) JP2016506719A (fr)
KR (1) KR20150103690A (fr)
CN (1) CN105142655B (fr)
AU (1) AU2013374516B2 (fr)
BR (1) BR112015017069A2 (fr)
CA (1) CA2897955C (fr)
DE (1) DE112013006456T5 (fr)
GB (1) GB2529557A (fr)
WO (1) WO2014112666A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101682096B1 (ko) * 2014-11-03 2016-12-02 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 신경안정용 조성물
KR101645652B1 (ko) * 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
KR101682093B1 (ko) * 2014-11-03 2016-12-02 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 혈압강하용 조성물
KR101737627B1 (ko) * 2014-11-27 2017-05-19 (주)퓨젠바이오 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 항산화용 조성물
KR101691972B1 (ko) * 2015-01-30 2017-01-02 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 암 예방 또는 치료용 약학 조성물
KR101712590B1 (ko) * 2015-08-06 2017-03-07 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 피로회복 증진용 조성물
KR101682108B1 (ko) * 2015-10-08 2016-12-02 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 혈행 개선용 조성물
KR101655882B1 (ko) * 2015-10-08 2016-09-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 숙취해소용 조성물
KR101655878B1 (ko) * 2015-10-08 2016-09-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 탈모방지 또는 발모촉진용 조성물
KR101682104B1 (ko) * 2015-11-26 2016-12-02 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 신장보호용 조성물
KR102150595B1 (ko) * 2017-06-30 2020-09-01 (주)퓨젠바이오 세리포리아 락세라타 배양액을 포함하는 상처 치료용 약학 조성물
KR101925890B1 (ko) * 2018-08-02 2018-12-06 김병천 신규한 세리포리아 라세라타-k1 균주 및 이의 배양물을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물
KR101981571B1 (ko) * 2018-10-12 2019-05-24 김병천 잔나비불로초 및 세리포리아 라세라타 k1 균사체를 이용한 이단 배양물을 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
KR101969433B1 (ko) * 2018-10-12 2019-04-17 김병천 잔나비불로초 및 세리포리아 라세라타 k1 균사체를 이용한 이단 배양물을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물
CN111518825B (zh) * 2020-04-30 2022-10-11 浙江工业大学 一种多基因组合表达制备蛹虫草多糖的方法
KR102297056B1 (ko) * 2020-08-20 2021-09-06 주식회사 마이셀랩 포로스테레움속 신균주 Porostereum sp.(KCTC18837P) 균사체 배양물 및 이를 유효성분으로 포함하는 당뇨병 예방 및 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102807956A (zh) * 2012-07-12 2012-12-05 华东理工大学 一株撕裂蜡孔菌菌株及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101138464B1 (ko) * 2004-07-06 2012-04-25 환인제약 주식회사 이노노투스 오블리쿠스 ｗｉ０６２８ 균주, 그의 항당뇨활성 추출물 및 추출방법
JP2008245629A (ja) * 2007-03-30 2008-10-16 Kyushu Univ 木質系廃棄物処理用微生物製剤
JP5561637B2 (ja) * 2010-02-16 2014-07-30 国立大学法人鳥取大学 きのこの揮発性抗菌物質を用いた防菌・除菌技術
KR101031605B1 (ko) * 2010-11-11 2011-04-27 김병천 당뇨병 질환의 예방 및 치료를 위한 세리포리아 락세라타 배양액 추출물의 제조방법 및 이에 따른 세리포리아 락세라타 배양액 추출물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102807956A (zh) * 2012-07-12 2012-12-05 华东理工大学 一株撕裂蜡孔菌菌株及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Crude extract of Ceriporia lacerata has a protective effecton dexamethasone-induced cytotoxicity in INS-1 cells via the modulation of PI3K/PKB activity;JI-HYE KIM, YU-KYOUNG PARK;《INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE》;20130426;第32卷(第1期);179-186 *
Hyperglycemic effect of submerged culture extract of Ceriporia lacerata in streptozotocin-induced diabetic rats;Ji-Eun Kim，Hyun-Jeong Kim;《Food Science and Biotechnology》;20121231;第21卷(第6期);1685-1693 *
一株撕裂蜡孔菌的分离培养及其系统发育分析;岳爱玲;《生物技术》;20101231;第20卷(第5期);第47-50页 *

Also Published As

Publication number Publication date
GB201514369D0 (en) 2015-09-30
KR20150103690A (ko) 2015-09-11
BR112015017069A2 (pt) 2017-07-11
WO2014112666A1 (fr) 2014-07-24
CN105142655A (zh) 2015-12-09
DE112013006456T5 (de) 2015-10-01
CA2897955C (fr) 2018-01-16
AU2013374516B2 (en) 2017-02-02
GB2529557A (en) 2016-02-24
JP2016506719A (ja) 2016-03-07
AU2013374516A1 (en) 2015-08-27
CA2897955A1 (fr) 2014-07-24

Similar Documents

Publication Publication Date Title
CN105142655B (zh) 由撕裂蜡孔菌培养基制备的提取物用于治疗糖尿病和糖尿病并发症
US20140193454A1 (en) Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient
Obaroakpo et al. α-Glucosidase and ACE dual inhibitory protein hydrolysates and peptide fractions of sprouted quinoa yoghurt beverages inoculated with Lactobacillus casei
Cheng et al. Studies on anti-inflammatory activity of sulfated polysaccharides from cultivated fungi Antrodia cinnamomea
EP3071212B1 (fr) Extrait d'algues pour son utilisation en tant qu'agent immunomodulateur
CN102959400B (zh) 受试物质的判定或评价方法
Thakur et al. 1-Deoxynojirimycin, its potential for management of non-communicable metabolic diseases
Sun et al. Polysaccharides from Agrocybe cylindracea residue alleviate type 2-diabetes-induced liver and colon injuries by p38 MAPK signaling pathway
Gao-Sheng et al. Accumulation of biomass and four triterpenoids in two-stage cultured Poria cocos mycelia and diuretic activity in rats
Oyeneye et al. Production of α-glycerylphosphorylcholine and other compounds from wheat fermentation
Kim et al. Hyperglycemic effect of submerged culture extract of Ceriporia lacerata in streptozotocin-induced diabetic rats
CN107198015A (zh) 双菌半干法发酵脱脂米糠获得活性物的方法
CN103564423A (zh) 灵芝提取物在制备具有抗辐射和抗衰老功效的保健食品或化妆品中的应用
Fan et al. Metabolomics reveals the effects of Lactiplantibacillus plantarum dy-1 fermentation on the lipid-lowering capacity of barley β-glucans in an in vitro model of gut-liver axis
JP6157706B2 (ja) セリポリア・ラセラタの培養液抽出物の調製方法およびこれから調製されたセリポリア・ラセラタの培養液抽出物を有効成分として含有する糖尿病性疾患および糖尿病合併症の予防または治療用の薬学的組成物
JP5390589B2 (ja) 血管新生阻害剤
CN115634241A (zh) 一种山东灵芝提取物的制备方法及其在制备降血糖药物中的应用
Alvandi et al. Optimization of soy-based media for the production of biologically active exopolysaccharides by medicinal mushroom trametes versicolor
CN108463123B (zh) 含有由撕裂蜡孔菌生成的胞外多糖作为有效成分的用于降血压的组合物
Wang et al. Dietary supplementation with Tolypocladium sinense mycelium prevents dyslipidemia inflammation in high fat diet mice by modulation of gut microbiota in mice
Phadannok et al. Enhancing glucose uptake by Astraeus odoratus and Astraeus asiaticus extracts in L6 myotubes
KR100963511B1 (ko) 제2형 당뇨치료 효과가 있는 상황 버섯 균사체 유래의항당뇨 활성 세포외다당체 및 그 제조방법
US20130189298A1 (en) Novel yeast strain and the application thereof
KR102297056B1 (ko) 포로스테레움속 신균주 Porostereum sp.(KCTC18837P) 균사체 배양물 및 이를 유효성분으로 포함하는 당뇨병 예방 및 치료용 조성물
Hwang et al. Modern Biotechnology of Phellinus baumii--From Fermentation to Proteomics.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Seoul, South Kerean

Applicant after: Kin Kin Biological Pharmaceutical Co., Ltd.

Address before: Seoul, South Kerean

Applicant before: FUGENBIO CO., LTD.

GR01 Patent grant
GR01 Patent grant